index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
107,chk2,protein,,chek2,uniprot,p00177,nucleus,go:0005739,atm,protein,,atm,uniprot,q03746,nucleus,go:0005739,positive,d,phosphorylation,t68,,b-cell,,vein,['2'],nan,nan,"during normal growth, chk2 is present in the nucleus in an inactive monomeric form (ahn et al., 2000). after dna damage, chk2 is phosphorylated by atm on the priming site t68 and on other residues in the scd (figure 2b). these phosphorylations lead to a conformational change which induces chk2 dimerization through binding of the phosphorylated scd of one monomer with the fha domain of another (ahn et al., 2002; xu et al., 2002). dimerization promotes chk2 autophosphorylation of the kinase domain at residues s260 and t432, the t-loop residues t383 and t387, and s516 (lee and chung, 2001; schwarz et al., 2003; wu and chen, 2003), triggering an additional conformational change and dissociation of the dimers into fully active monomers. although phosphorylation of the scd is the initial, essential step of chk2 activation, this domain is rapidly dephosphorylated, perhaps because after dimer dissociation it is exposed to phosphatases (ahn et al., 2002). therefore, scd phosphorylation is detectable only at early time points after damage.",pmc4296918,1,10,20,1,30
78,cdk,protein,,cdkn1a,uniprot,q92579,cytoplasm,go:0005739,ap-1,protein,,jun,uniprot,p00756,nucleus,go:0005634,positive,d,phosphorylation,,t cells,t cell,,human,['27'],nan,nan,requirement for cdk activity in ap-1 activation and il-6 production,pmc3084876,1,10,19,1,29
92,cdk4,protein,,cdkn2a,uniprot,p13248,cytoplasm,go:0005634,c-jun,protein,,jun,uniprot,p00738,nucleus,go:0005634,positive,d,phosphorylation,,,b-cell,,,['20'],nan,nan,"the ability of cdk4 to phosphorylate c-jun. additionally, the activity of ap-1,",pmc3084876,1,10,19,1,29
105,chk1,protein,,chek1,uniprot,p00339,cytoplasm,go:0005634,mtor,protein,,rps6kb1,uniprot,q92019,cytoplasm,go:0005634,negative,d,inhibits,,breast cancer,epithelial,,human,['482'],nan,nan,"we could consistently show that dna damage-induced chk1 activation was dependent on mtor in all cell lines studied, suggesting that cells may rely on mtor-chk1 signalling for survival. numerous studies have demonstrated that chk1 inhibition following dna damage potentiates dna damage-induced cell death via multiple mechanisms [48-53]. importantly, this study has revealed an unexpected benefit of mtorc1/2 inhibitors in their ability to inhibit chk1 activity and cell cycle arrest. we show reduced cell survival when mtorc1/2 is inhibited in the presence of genotoxic stress and report that mtorc2 is essential for chk1 activation. our data provides new mechanistic insight into the role of mtor in the dna damage response and support the clinical development of mtorc1/2 inhibitors in combination with dna damage-based therapies for breast cancer.",pmc4381605,1,10,19,1,29
154,egfr,protein,,egfr,uniprot,p14680,plasma membrane,go:0005886,src,protein,,src,uniprot,q03742,plasma membrane,go:0005886,positive,d,phosphorylation,,,epithelial-like,,human,['223'],nan,nan,"ligand-activated egfr undergoes autophosphorylation on multiple tyrosine residues, most of which are located in the c-terminal non-catalytic sequence; they include y992, y1068, y1086, y1148, and y1173 [7,22–26]. later studies showed that tyrosine residues in egfr could also be phosphorylated by other kinases including src (y845, for detail see below; y891 and y920 [27]; y1045 [28]; y1101 [20]; y1173 [29]). the phosphorylation of serine and threonine residues in egfr was also found: it included t654, t669, s967, s971, s1002, and s1046/s1047 [15,16,30–32]. several lines of evidence indicate that the autophosphorylated tyrosine residues serve as docking sites for a variety of signaling molecules that contain a phosphotyrosine-binding sequence (i.e., src homology 2 or phosphotyrosine-binding domains). on the other hand, serine/threonine phosphorylation acts as a regulatory mechanism for the dimerization, catalytic activity, and/or turnover of the protein [8].",pmc3709701,1,10,19,1,29
155,egfr,protein,,egfr,uniprot,q05537,plasma membrane,go:0005886,igf-1r,protein,,igf1r,uniprot,q07817,mitochondria,go:0005739,positive,d,signal transduction,,,,,human,['207'],nan,nan,"survival signals like growth factors, cytokines and hormones activate phosphatidylinositol 3-kinase (pi3k) [155]. subsequently, pi3k activates akt/pkb [156] that interferes with the apoptotic machinery. activated akt/pkb mediate cell survival via the regulation of numerous apoptotic relevant proteins such as the bcl-2 family members bad and bcl-xl and the transcription factor nf-κb [157,158]. survival signaling by akt is counteracted by pten that antagonizes the action of pi3k. pi3k and akt are overexpressed in a variety of cancers [159,160]. in addition, pten is frequently deleted in advanced tumors [161,162]. these alterations lead to a 'constitutively active' survival-signaling pathway that enhances the insensitivity of tumor cells to apoptosis induction. additionally, egfr directly influences pi3k [163]. because pi3k mediates survival signals, egfr overexpression leads to a decrease in the apoptotic response and therefore a stronger survival of cancer cells. recent work has shown that the igf-1r suppresses apoptosis by signaling through pi3k and akt [120]. activated akt in turn phosphorylates the intracellular transducer, bad, which modulates the activity of the apoptosis suppressors bcl-2 and bcl-xl [164]. additionally, akt can directly phosphorylate caspase-9, which leads to inactivation of caspase-9 [165]. strategies are pursued that aim to block the enzymatic activity of pi3k and pkb/akt, in order to prevent inactivation of pro-apoptotic bad. wortmannin was shown to be a potent inhibitor of pi3k [160]. in several cancers including non-small-cell lung cancer [160] and pancreatic cancer [166], treatment of cells with wortmannin leads to inhibition of proliferation and increased apoptosis. additionally, wortmannin enhanced gemcitabine-induced apoptosis in human pancreatic cells in vitro [167] and in vivo [168]. in contrast, studies investigating different pancreatic cancer cell lines pointed out that the pi3k/akt pathway is not involved in gemcitabine-resistance [a. arlt, unpublished data]. neither did the basal akt-activity correlate with the sensitivity towards gemcitabine treatment, nor did the inhibition of pi3k/akt alter gemcitabine-induced apoptosis.",pmc149420,1,10,19,1,29
350,p27,protein,,cdkn1a,uniprot,p00674,cytoplasm,go:0005634,s6,protein,,,uniprot,s6,cytoplasm,go:0005634,negative,d,inhibits,,,b-cell,,human,['64'],nan,nan,"by tracking the upstream pathways responsible for s6 phosphorylation, we found that neither p70s6k nor akt was involved based on the findings that knocking down p70s6k and loss of the kinase activity of akt by introducing dominant-negative mutations, k197m and t308/s473a, did not alter s6 phosphorylation. in contrast, blockage of ras/raf/mer/erk pathway by transfecting dominant-negative ras (s17n) and erk1/2 (k71/52r) into p27−/−(δ51) cells attenuated s6 phosphorylation, suggesting that p27 negatively controlled s6 activation by inhibiting the ras/raf/mer/erk/p90rsk pathway. the mechanistic investigation further revealed that p27 maintained phlpp protein expression, which hampered ras activation. phlpp is a newly identified family of ser/thr pp and catalyzes the dephosphorylation of a conserved regulatory motif, the hydrophobic motif, on the agc kinases of akt, pkc and p70s6k, as well as an inhibitory site on the kinase mst1, to inhibit cellular proliferation and induce apoptosis.49 therefore, phlpp is generally regarded as a novel tumor suppressor, and the frequent deletion of phlpp is observed in human cancers.49 the recent findings further showed that phlpp possessed a novel function in inhibiting ras activation.32, 33 distinct from the mechanisms of gaps, phlpp binds to the nucleotide-free ras, which occurs during ras switching from gtp-bound form to gdp-bound form, and in turn abrogates ras binding with gtp, further leading to repression of downstream erk pathway activation.32, 33 phlpp expression can be regulated at the translational level by mir-190 in a p50-dependent manner;50, 51 however, p27 might control phlpp expression in an mir-190-independent manner (zhang and huang et al., unpublished data).",pmc4260754,1,10,19,1,29
366,p53,protein,tumor suppressor,tp53,uniprot,q04272,nucleus,go:0005739,atm,protein,kinase,atr,uniprot,p04978,nucleus,go:0005739,positive,i,binds,,,,,human,['4'],nan,nan,"cells with irreparable damage activate apoptotic pathways, to avoid propagation of a modified, potentially harmful genome. the induction of apoptosis proceeds through at least two main pathways (extrinsic and intrinsic), each of which can be regulated at multiple levels. a common regulator of both these apoptotic pathways is p53, a transcription factor and tumor suppressor protein that, in response to dna damage, induces the expression of genes involved in checkpoint activation or apoptosis (gomez-lazaro et al., 2004). in unstressed cells, p53 has low activity and a short half-life because it is complexed with two proteins, the e3 ubiquitin protein ligase (mdm2) and the mdm2-like p53-binding protein (hdmx), which cause p53 to be ubiquitinated and degraded by proteasomes; low p53 levels and activity allow normal growth (gomez-lazaro et al., 2004). after dna damage, p53 is phosphorylated by atm, an event that displaces mdm2 and allows p53 to accumulate in the nucleus where it can perform its function as transcription factor (cheng and chen, 2010). this p53 stabilization is also due to the degradation of hdmx, which is induced by phosphorylation by both atm and chk2 (chen et al., 2005b; lebron et al., 2006; pereg et al., 2006). indeed, hdmx normally shuttles between the nucleus and the cytoplasm, but in the presence of dsbs, nuclear hdmx is phosphorylated by atm and chk2 and retained there through binding to 14-3-3 proteins (chen et al., 2005b). this event is an essential step toward hdmx degradation, p53 activation and apoptosis induction (figure 3c).",pmc4296918,1,10,19,1,29
399,pi3k,protein,,pi3k,uniprot,p00018,plasma membrane,go:0005886,insulin receptor,protein,,insr,uniprot,q04635,plasma membrane,go:0005886,positive,d,phosphorylation,,,b-cell,,vein,['96'],nan,nan,"the signal transduction mechanisms operating downstream of insulin receptor ligation have highlighted the importance both of the receptor tyrosine kinase substrates (insulin receptor substrates, irs-1 and irs-2) and the lipid kinase phosphoinositide 3-oh kinase (pi3k; saltiel, 2001; saltiel and kahn, 2001; cantley, 2002; white, 2002). activation of pi3k occurs via recruitment to irs proteins, and is critical in generating many of the cell's responses to insulin (shepherd et al., 1998). the insulin–pi3k pathway also plays a conserved role in regulating cell and organism size. mice deficient in effectors of pi3k, pdk1 and s6k1, exhibit growth defects (shima et al., 1998; lawlor et al., 2002), whereas activation of pi3k leads to increases in cell and organ growth (leevers et al., 1996; crackower et al., 2002; shioi et al., 2002). the growth response to insulin-like growth factors involves the s6 kinases and leads to increased translation of 5′-terminal oligopyrimidine track mrnas (jefferies et al., 1997), many of which encode ribosomal proteins. by increasing ribosome biogenesis, activation of s6k is thought to lead to an increase in protein synthesis (volarevic and thomas, 2001). two s6k genes, s6k1 and s6k2, together encode four kinase isoforms, three of which are present in the nucleus (reinhard et al., 1992; gout et al., 1998). two signaling pathways have been shown to positively regulate s6k: the insulin–pi3k pathway (reif et al., 1997; martin et al., 2001) and a nutrient pathway involving the mammalian target of rapamycin (mtor; brown et al., 1995; park et al., 2002). a genetic regulator of s6k1 activity has also been identified—the tumor suppressor tuberous sclerosis complex (tsc1-2), a complex of the tsc1 and tsc2 gene products, hamartin and tuberin (van slegtenhorst et al., 1998). inactivation of tsc1-2 leads to constitutive s6k1 activity (jaeschke et al., 2002; kwiatkowski et al., 2002) and growth in drosophila (ito and rubin, 1999; gao and pan, 2001; potter et al., 2001; tapon et al., 2001). an inhibitory target of tsc1-2 action has been identified as rheb, a small gtpase (garami et al., 2003; saucedo et al., 2003; stocker et al., 2003; y. zhang et al., 2003) with rheb overexpression resulting in activation of s6k (for review see li et al., 2004).",pmc2172316,1,10,19,1,29
483,s6k,protein,,s6k1,uniprot,q02804,plasma membrane,go:0005886,insulin receptor,protein,,insr,uniprot,q02804,plasma membrane,go:0005886,negative,d,binds,,mef,fibroblast,,mouse,['109'],nan,nan,"starved mefs (jaeschke et al., 2002) were stimulated with 1 μg/ml insulin, 50 ng/ml igf-i, or 20 ng/ml egf for 10 min. cho-ir cells were maintained in ham's f12 medium with 10% fcs and were starved in medium lacking serum for 24 h. to activate insulin receptors, cells were then stimulated for 10 min with 1 μm insulin. sirnas (dharmacon) for s6k were: s6k1, 5′-ggacatggcaggagtgttt-3′; and s6k2, 5′-gaaccaagaagtccaagaa-3′.",pmc2172316,1,10,19,1,29
530,tsc1,protein,,tsc1,uniprot,q92679,cytoplasm,go:0005634,tsc2,protein,,tsc2,uniprot,q92680,cytoplasm,go:0005634,negative,d,phosphorylation,,nsclc,epithelial,lung,human,['350'],nan,nan,"tsc1-tsc2 complexes have recently been implicated in cell survival responses. the molecular mechanisms by which tsc2 affects mtor-related signals remain unclear. we found that knockdown of tsc2 resulted in inhibition of the effect of rosiglitazone on the mtor downstream target p70s6k suggesting a role for tsc2 in mediating this effect. in cell proliferation assays, we showed that the tsc2 sirna partially restored nsclc cell growth in the presence of rosiglitazone, although knockdown of tsc2 alone had no effect on nsclc cell proliferation. this suggests that tsc2 does not contribute to nsclc cell proliferation at baseline, but its phosphorylation partially mediates the growth inhibitory effect of rosiglitazone.",pmc1892639,1,10,18,1,28
